Drug
Abt 874
Abt 874: highest development phase Phase 3, developed by AbbVie. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- AbbVie
Trials
| Drug | Phase | Indication |
|---|---|---|
| ABT-874 NCT00626002 | Phase 3 | Moderate to Severe Plaque Psoriasis |
Latest
No recent events.
Follow Abt 874 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.